Oncolytic Virotherapy

• 

  Subject Areas on Research

  • A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. 
  • Combination strategies to maximize the benefits of cancer immunotherapy. 
  • Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. 
  • Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells. 
  • Emerging immunotherapies for glioblastoma. 
  • Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer. 
  • Enhanced oncolytic virotherapy through oxidative stress inhibition. 
  • Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. 
  • Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. 
  • Growth phenotypes and biosafety profiles in poliovirus-receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses. 
  • Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. 
  • Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. 
  • Injectable Therapies for Regional Melanoma. 
  • MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. 
  • Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. 
  • Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. 
  • Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. 
  • Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. 
  • Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. 
  • Oncolytic polio virotherapy of cancer. 
  • Oncolytic virus-derived type I interferon restricts CAR T cell therapy. 
  • Oncolytic viruses in melanoma. 
  • Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. 
  • Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. 
  • Recent clinical progress in virus-based therapies for cancer. 
  • Recombinant Poliovirus for Cancer Immunotherapy. 
  • Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. 
  • Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. 
  • Recurrent Glioblastoma Treated with Recombinant Poliovirus. 
  • Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. 
  • Vaccine Therapy, Oncolytic Viruses, and Gliomas. 
  • Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. 
  • Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. 
  • Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. 
  • Virus-based therapies for colon cancer. 
  • Viruses in the treatment of malignant glioma. 
  • White paper on microbial anti-cancer therapy and prevention. 
• 

  Keywords of People

  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering